Literature DB >> 11382092

Estimating the costs of caring for people with Alzheimer disease in California: 2000-2040.

P J Fox1, N Kohatsu, W Max, P Arnsberger.   

Abstract

The costs of caring for people with Alzheimer disease (AD) in California are estimated using data from a study of the costs of caring for community-resident and institutionalized people with AD, combined will prevalence and population projections. Costs for community-resident patients will increase 83 percent in the period 2000 ($23.4 billion) to 2020 ($42.8 billion), and will grow an additional 59 percent from 2020 to 2040 ($68.1 billion). Costs for AD patients in institutions will increase 84 percent from 2000 ($2.5 billion) to 2020 ($4.6 billion), and will grow an additional 61 percent from 2020 to 2040 ($7.4 billion), assuming the supply of nursing home beds meets projected demand. Total costs of caring for AD patients will nearly triple between 2000 and 2040. The rapid aging of the U.S. population makes more aggressive societal action necessary if the personal and societal burden of Alzheimer's disease is to be reduced in the future.

Entities:  

Mesh:

Year:  2001        PMID: 11382092

Source DB:  PubMed          Journal:  J Public Health Policy        ISSN: 0197-5897            Impact factor:   2.222


  7 in total

1.  Contrary to stereotypes, a nursing home resident radiates dignity and joy.

Authors:  Susan Ladwig; Elizabeth Fee; Theodore M Brown
Journal:  Am J Public Health       Date:  2006-05-30       Impact factor: 9.308

Review 2.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

3.  Deep brain stimulation for Alzheimer disease: a decision and cost-effectiveness analysis.

Authors:  Keyvan Mirsaeedi-Farahani; C H Halpern; G H Baltuch; D A Wolk; S C Stein
Journal:  J Neurol       Date:  2015-03-06       Impact factor: 4.849

4.  Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.

Authors:  Philippe Bordier; Stephane Garrigue; Stephane Lanusse; Julien Margaine; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Causes of syncope in patients with Alzheimer's disease treated with donepezil.

Authors:  Philippe Bordier; Stephane Lanusse; Stephane Garrigue; Charlotte Reynard; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  ORAL HEALTH IN NURSING HOMES: WHAT WE KNOW AND WHAT WE NEED TO KNOW.

Authors:  Andriana M Foiles Sifuentes; Kate L Lapane
Journal:  J Nurs Home Res Sci       Date:  2020

Review 7.  A Review of the Current Mammalian Models of Alzheimer's Disease and Challenges That Need to Be Overcome.

Authors:  Natasha Elizabeth Mckean; Renee Robyn Handley; Russell Grant Snell
Journal:  Int J Mol Sci       Date:  2021-12-06       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.